CTL inducer composition
The present invention provides a CTL inducer composition which comprises one or more peptides selected from the group consisting of the peptides of SEQ ID NOS: 1 to 27 in the Sequence Listing, and can be used for the treatment or prevention of cancer or a hepatitis C virus-related disease in two or more patient groups selected from the group consisting of an HLA-A2 positive patient group, an HLA-A24 positive patient group, an HLA-A26 positive patient group, and an HLA-A3 supertype positive patient group.
1. A method for the treatment of cancer in an HLA-A3 supertype positive patient, which comprises administering a cytotoxic T lymphocyte inducer composition which comprises one or more peptides selected from the group consisting of SART3-302 (SEQ ID NO: 9), Lck-246 (SEQ ID NO: 10), ppMAPkkk-432 (SEQ ID NO: 11), and HNRPL-501 (SEQ ID NO: 14) to an HLA-A3 supertype positive patient.
2. The method of claim 1 , wherein the HLA-A3 supertype is HLA-A11 or HLA-A31.
3. The method of claim 1 , wherein the administration of the cytotoxic T lymphocyte inducer composition comprises intradermal administration or subcutaneous administration.
4. The method of claim 1 , wherein the one or more peptides are administered in an amount of 0.1 to 5 mg.
5. A method for the treatment of cancer in an HLA-A26 positive patient, which comprises administering a cytotoxic T lymphocyte inducer composition which comprises one or more peptides selected from the group consisting of ppMAPkkk-432 (SEQ ID NO: 11) and HNRPL-501 (SEQ ID NO: 14) to an HLA-A26 positive patient.
6. The method of claim 5 , wherein the administration of the cytotoxic T lymphocyte inducer composition comprises intradermal administration or subcutaneous administration.
7. The method of claim 5 , wherein the one or more peptides are administered in an amount of 0.1 to 5 mg.
8. A method for the treatment of cancer in an HLA-A24 positive patient, which comprises administering a cytotoxic T lymphocyte inducer composition which comprises HNRPL-501 (SEQ ID NO: 14) to an HLA-A24 positive patient.
9. The method of claim 8 , wherein the administration of the cytotoxic T lymphocyte inducer composition comprises intradermal administration or subcutaneous administration.
10. The method of claim 8 , wherein the one or more peptides are administered in an amount of 0.1 to 5 mg.